^
Association details:
| Biomarker: | PTEN negative |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | ipatasertib (RG7440) (PI3K inhibitor, AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer
Published date:
02/08/2021
Excerpt:
Consistent benefit with the combination arm vs pbo + abi was observed when PTEN loss by IHC was defined more stringently (rPFS at ≥ 60% tumor cells with PTEN loss…Analyses of more-stringent biomarkers associated with activation of the PI3K/AKT pathway further support ipat + abi as a treatment option for first-line mCRPC...
Secondary therapy:
abiraterone acetate
DOI:
10.1200/JCO.2021.39.6_suppl.13
Trial ID:
